Why the study?
Does amiodarone improve symptoms in patients with drug-resistant supraventricular and ventricular arrhythmias?
Does amiodarone improve symptoms in patients with drug-resistant supraventricular and ventricular arrhythmias?
Amiodarone is effective for drug-resistant arrhythmias, though patients must be monitored for side effects and the development of tolerance.
Amiodarone may benefit refractory arrhythmia patients; hypothesis-generating from 8 cases and requires randomized confirmation before practice change.
Amiodarone is used in the treatment of previously drug-resistant supraventricular and ventricular arrhythmias. We report our experience with amiodarone in 8 patients. Five patients had paroxysmal atrial flutter, one had paroxysmal atrial fibrillation, one had supraventricular tachycardia, and one ventricular tachycardia. Considerable improvement, both objectively and subjectively, was observed in all patients. Side effects were as follows: all patients had corneal microdeposits, one developed left bundle branch block which resolved on stopping amiodarone, and one reported constipation and abdominal pains. Six patients have been treated for 10-28 months; 3 developed tolerance at 4-14 months after the introduction of amiodarone therapy, but symptoms improved with increased dosage. It is important to watch for the development of tolerance to this drug.
No takes yet. Share an insight, caveat, or question.
Hollman et al. (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: